Meridian Bioscience (Nasdaq: VIVO ) reported earnings on April 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q2), Meridian Bioscience beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share increased significantly.
Gross margins contracted, operating margins increased, net margins increased.
Meridian Bioscience booked revenue of $47.4 million. The eight analysts polled by S&P Capital IQ foresaw revenue of $45.4 million on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $41.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.23. The 10 earnings estimates compiled by S&P Capital IQ predicted $0.21 per share. GAAP EPS of $0.23 for Q2 were 28% higher than the prior-year quarter's $0.18 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 62.7%, 180 basis points worse than the prior-year quarter. Operating margin was 31.7%, 140 basis points better than the prior-year quarter. Net margin was 20.3%, 260 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $46.5 million. On the bottom line, the average EPS estimate is $0.22.
Next year's average estimate for revenue is $181.0 million. The average EPS estimate is $0.83.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 463 members out of 475 rating the stock outperform, and 12 members rating it underperform. Among 118 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 117 give Meridian Bioscience a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is hold, with an average price target of $20.00.
Can your retirement portfolio provide you with enough income to last? You'll need more than Meridian Bioscience. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.